NASDAQ:ABMDABIOMED Stock Price, Forecast & News

ABIOMED's stock was trading at $151.13 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, ABMD shares have increased by 80.1% and is now trading at $272.26. View which stocks have been most impacted by Coronavirus.

9 Wall Street analysts have issued "buy," "hold," and "sell" ratings for ABIOMED in the last year. There are currently 1 sell rating, 4 hold ratings and 4 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View analyst ratings for ABIOMED.

ABIOMED is scheduled to release its next quarterly earnings announcement on Thursday, August 6th 2020. View our earnings forecast for ABIOMED.

ABIOMED, Inc. (NASDAQ:ABMD) announced its earnings results on Thursday, April, 30th. The medical equipment provider reported $0.70 earnings per share (EPS) for the quarter, missing the Zacks' consensus estimate of $0.96 by $0.26. The medical equipment provider earned $206.66 million during the quarter, compared to analyst estimates of $209.58 million. ABIOMED had a return on equity of 18.51% and a net margin of 24.14%. The firm's quarterly revenue was down .2% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $1.60 earnings per share. View ABIOMED's earnings history.

9 brokerages have issued twelve-month price targets for ABIOMED's stock. Their forecasts range from $152.00 to $240.00. On average, they anticipate ABIOMED's stock price to reach $193.00 in the next twelve months. This suggests that the stock has a possible downside of 29.1%. View analysts' price targets for ABIOMED.

Headlines about ABMD stock have trended positive on Thursday, according to InfoTrie Sentiment. InfoTrie ranks the sentiment of press coverage by monitoring more than six thousand news and blog sources. The firm ranks coverage of public companies on a scale of -5 to 5, with scores nearest to five being the most favorable. ABIOMED earned a news sentiment score of 2.1 on InfoTrie's scale. They also gave news coverage about the medical equipment provider a news buzz of 10.0 out of 10, meaning that recent press coverage is extremely likely to have an effect on the company's share price in the next several days. View the latest news about ABIOMED.

ABIOMED saw a decline in short interest during the month of June. As of June 30th, there was short interest totaling 2,360,000 shares, a decline of 13.6% from the June 15th total of 2,730,000 shares. Based on an average daily trading volume, of 559,700 shares, the days-to-cover ratio is presently 4.2 days. Currently, 5.4% of the shares of the company are short sold. View ABIOMED's Current Options Chain.

Some companies that are related to ABIOMED include Abbott Laboratories (ABT), Medtronic (MDT), Becton Dickinson and (BDX), Intuitive Surgical (ISRG), Stryker (SYK), Boston Scientific (BSX), Edwards Lifesciences (EW), Baxter International (BAX), DexCom (DXCM), IDEXX Laboratories (IDXX), ResMed (RMD), Teleflex (TFX), Hologic (HOLX), Steris (STE) and Insulet (PODD). View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other ABIOMED investors own include NVIDIA (NVDA), Alibaba Group (BABA), Micron Technology (MU), Align Technology (ALGN), Netflix (NFLX), Arista Networks (ANET), Square (SQ), Paypal (PYPL), salesforce.com (CRM) and Adobe (ADBE).

ABIOMED trades on the NASDAQ under the ticker symbol "ABMD."

ABIOMED's stock is owned by many different retail and institutional investors. Top institutional shareholders include Scout Investments Inc. (0.27%), Rhenman & Partners Asset Management AB (0.15%), West Coast Financial LLC (0.03%), Envestnet Asset Management Inc. (0.02%), State of Alaska Department of Revenue (0.02%) and IFM Investors Pty Ltd (0.01%). Company insiders that own ABIOMED stock include Andrew J Greenfield, David M Weber, Martin P Sutter and Michael G Howley. View institutional ownership trends for ABIOMED.

ABMD stock was sold by a variety of institutional investors in the last quarter, including Rhenman & Partners Asset Management AB, IFM Investors Pty Ltd, and Coe Capital Management LLC. View insider buying and selling activity for ABIOMED.

ABMD stock was acquired by a variety of institutional investors in the last quarter, including Scout Investments Inc., West Coast Financial LLC, Legacy Capital Partners Inc., Envestnet Asset Management Inc., Exchange Traded Concepts LLC, Contravisory Investment Management Inc., Cypress Capital Group, and IBM Retirement Fund. View insider buying and selling activity for ABIOMED.

Shares of ABMD can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of ABMD stock can currently be purchased for approximately $272.26.

ABIOMED has a market capitalization of $12.26 billion and generates $840.88 million in revenue each year. The medical equipment provider earns $203.01 million in net income (profit) each year or $4.74 on an earnings per share basis. ABIOMED employs 1,536 workers across the globe.

The official website for ABIOMED is www.abiomed.com.

ABIOMED's mailing address is 22 CHERRY HILL DR, DANVERS MA, 01923. The medical equipment provider can be reached via phone at 978-646-1400 or via email at [email protected]